DongKook Pharmaceutical Toekomstige groei
Future criteriumcontroles 2/6
DongKook Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 14.4% en 9.4% per jaar. De winst per aandeel zal naar verwachting groeien met 14.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.1% zijn.
Belangrijke informatie
14.4%
Groei van de winst
14.1%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 33.3% |
| Inkomstengroei | 9.4% |
| Toekomstig rendement op eigen vermogen | 11.1% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 25 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Investors Are Less Pessimistic Than Expected
Aug 07
These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well
May 29We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt
May 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 06How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?
Mar 15The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?
Feb 28DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?
Feb 14
DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly
Feb 01DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 19The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio
Jan 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting
Dec 21What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?
Dec 08The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It
Nov 23Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 962,500 | 78,500 | N/A | 80,500 | 1 |
| 12/31/2025 | 876,300 | 69,100 | N/A | 71,900 | 1 |
| 12/31/2024 | 794,600 | 60,200 | N/A | 80,200 | 1 |
| 6/30/2024 | 764,673 | 54,480 | 4,190 | 44,313 | N/A |
| 3/31/2024 | 747,013 | 50,812 | 5,645 | 43,834 | N/A |
| 12/31/2023 | 730,994 | 47,175 | 2,203 | 41,793 | N/A |
| 9/30/2023 | 709,543 | 47,276 | -4,834 | 38,961 | N/A |
| 6/30/2023 | 692,794 | 46,959 | 6,550 | 41,667 | N/A |
| 3/31/2023 | 676,772 | 53,131 | 7,390 | 43,763 | N/A |
| 12/31/2022 | 661,647 | 52,896 | -11,064 | 40,909 | N/A |
| 9/30/2022 | 645,744 | 58,943 | -2,673 | 45,738 | N/A |
| 6/30/2022 | 631,065 | 55,611 | -12,494 | 48,082 | N/A |
| 3/31/2022 | 615,974 | 50,919 | -16,170 | 49,477 | N/A |
| 12/31/2021 | 594,193 | 50,345 | -5,022 | 44,654 | N/A |
| 9/30/2021 | 585,740 | 43,945 | 1,639 | 47,422 | N/A |
| 6/30/2021 | 588,360 | 52,484 | 25,343 | 60,698 | N/A |
| 3/31/2021 | 572,391 | 54,515 | 5,616 | 48,930 | N/A |
| 12/31/2020 | 559,103 | 55,925 | 17,814 | 59,108 | N/A |
| 9/30/2020 | 544,685 | 63,502 | 19,859 | 65,202 | N/A |
| 6/30/2020 | 520,469 | 61,569 | 13,244 | 59,474 | N/A |
| 3/31/2020 | 502,390 | 60,360 | 38,679 | 68,633 | N/A |
| 12/31/2019 | 482,280 | 56,312 | 44,377 | 69,483 | N/A |
| 9/30/2019 | 456,230 | 53,797 | -13,023 | 60,123 | N/A |
| 6/30/2019 | 436,293 | 50,618 | -28,598 | 49,945 | N/A |
| 3/31/2019 | 418,583 | 49,157 | -40,695 | 32,790 | N/A |
| 12/31/2018 | 400,807 | 46,949 | -42,324 | 33,209 | N/A |
| 9/30/2018 | 391,801 | 45,695 | 8,925 | 30,618 | N/A |
| 6/30/2018 | 378,388 | 42,872 | 24,480 | 36,546 | N/A |
| 3/31/2018 | 366,905 | 41,695 | N/A | 41,149 | N/A |
| 12/31/2017 | 354,768 | 39,602 | N/A | 28,659 | N/A |
| 9/30/2017 | 342,293 | 38,070 | N/A | 28,869 | N/A |
| 6/30/2017 | 330,629 | 39,996 | N/A | 28,465 | N/A |
| 3/31/2017 | 320,349 | 40,421 | N/A | 34,431 | N/A |
| 12/31/2016 | 309,690 | 40,660 | N/A | 39,412 | N/A |
| 9/30/2016 | 302,007 | 38,101 | N/A | 42,036 | N/A |
| 6/30/2016 | 292,760 | 35,192 | N/A | 40,984 | N/A |
| 3/31/2016 | 275,174 | 30,488 | N/A | 36,877 | N/A |
| 12/31/2015 | 259,930 | 27,426 | N/A | 27,143 | N/A |
| 9/30/2015 | 244,766 | 23,139 | N/A | 20,752 | N/A |
| 6/30/2015 | 234,686 | 21,380 | N/A | 16,372 | N/A |
| 3/31/2015 | 228,197 | 20,811 | N/A | 17,437 | N/A |
| 12/31/2014 | 226,014 | 21,098 | N/A | 22,737 | N/A |
| 9/30/2014 | 224,391 | 18,107 | N/A | 22,406 | N/A |
| 6/30/2014 | 220,612 | 18,859 | N/A | 21,157 | N/A |
| 3/31/2014 | 218,094 | 17,552 | N/A | 20,954 | N/A |
| 12/31/2013 | 213,086 | 16,764 | N/A | 19,860 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei A086450 ( 14.4% per jaar) ligt boven de spaarquote ( 2.7% ).
Winst versus markt: De winst van A086450 ( 14.4% per jaar) zal naar verwachting langzamer groeien dan de markt KR ( 28.4% per jaar).
Hoge groeiwinsten: De winst van A086450 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van A086450 ( 9.4% per jaar) zal naar verwachting sneller groeien dan de markt KR ( 9.4% per jaar).
Hoge groei-inkomsten: De omzet van A086450 ( 9.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen A086450 zal naar verwachting over 3 jaar laag zijn ( 11.1 %).